TY - JOUR
T1 - The importance of an early onset of migraine prevention
T2 - an evidence-based, hypothesis-driven scoping literature review
AU - Gottschalk, Christopher
AU - Buse, Dawn C.
AU - Marmura, Michael J.
AU - Torphy, Bradley
AU - Pavlovic, Jelena M.
AU - Dumas, Paula K.
AU - Lalvani, Nim
AU - Blumenfeld, Andrew
N1 - Funding Information:
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: C.G. has been a paid consultant for Alder/Lundbeck, Biohaven, Amgen/Novartis, Theranica, Axsome, Upsher Smith, Spherix Global Insights, and Vorso and has been a past member of speaker bureaus for Amgen/Novartis, Allergan/AbbVie, Biohaven, Lilly, Theranica, and Upsher Smith. He served as an Associate Editor of Headache until 2020 and is a board member of the Headache Cooperative of New England (HCNE). D.C.B. has received grant support from the Food and Drug Administration and the National Headache Foundation and grant support and honoraria from Allergan, Amgen, Lilly, Lundbeck, and Teva. She serves on the editorial board of Current Pain and Headache Reports. M.J.M. has received compensation for consultation from Lundbeck and Theranica. He has participated in speaker bureaus for Lilly and Amgen/Novartis. He has received salary support for serving as principal investigator from Teva, GammaCore, and Allergan/AbbVie. He has received payments for authorship or royalties from Demos Medical, Cambridge University Press, and MedLink.
Funding Information:
The authors thank Dr. Anirban Basu for his participation in the advisory board and input on this work. The authors also thank Philip Sjostedt, BPharm, MPH, of The Medicine Group, LLC (New Hope, PA, United States) for providing medical writing support, which was funded by Lundbeck LLC (Deerfield, IL, USA) and in accordance with Good Publication Practice guidelines. The authors have authorized the submission of this manuscript by The Medicine Group on their behalf and have approved any statements and declarations. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This scoping literature review was sponsored and funded by H. Lundbeck A/S and Lundbeck Seattle BioPharmaceuticals, Inc. All authors prepared, reviewed, and approved the article, and made the decision to submit the article for publication. Editorial support for the development of this article was funded by H. Lundbeck A/S.
Funding Information:
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This scoping literature review was sponsored and funded by H. Lundbeck A/S and Lundbeck Seattle BioPharmaceuticals, Inc. All authors prepared, reviewed, and approved the article, and made the decision to submit the article for publication. Editorial support for the development of this article was funded by H. Lundbeck A/S.
Publisher Copyright:
© The Author(s), 2022.
PY - 2022
Y1 - 2022
N2 - Recently approved migraine preventive therapies facilitate rapid control of migraine activity, potentially improving patients’ lives and minimizing the societal burden of migraine. This review synthesizes available evidence on rates and timing of early onset of migraine prevention and identifies patient-level outcomes related to early onset prevention. This evidence-based scoping review identified all available clinical trial evidence regarding the early onset of prevention of migraine, under the hypothesis ‘Patients with migraine (episodic or chronic) report additional benefits when receiving an approved migraine preventive treatment that demonstrates an early onset of prevention’. Early onset of prevention was defined as migraine preventive benefits within 30 days post-administration. PubMed, EMBASE, and CINAHL were searched for publications between 1988 and 2020. Overall, 16 publications described 18 studies. All studies were conducted in approved treatments [four anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies and one chemodenervation agent] in patients with episodic/chronic migraine; no publications were identified for traditional oral agents for early migraine prevention. Compared to placebo, erenumab (three studies) reduced weekly migraine days within 1 week; fremanezumab (six studies) increased reports of no headache of at least moderate severity on Day 1 and significantly reduced migraine frequency within 1 week; galcanezumab (three studies) significantly reduced the mean number of patients with migraine beginning Day 1 and each day of the first week; eptinezumab (four studies) significantly reduced migraine attack likelihood on Day 1 by > 50% versus baseline; and onabotulinumtoxinA (two studies) reduced headache and migraine days within 1 week. Four publications described function, disability, and quality of life improvements as early as Week 4; none reported cost–benefit. Anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) and a chemodenervation agent (onabotulinumtoxinA) provide clinically relevant benefits during the first treatment week. Literature describing clinically relevant benefits regarding early onset of prevention in patients with migraine is limited.
AB - Recently approved migraine preventive therapies facilitate rapid control of migraine activity, potentially improving patients’ lives and minimizing the societal burden of migraine. This review synthesizes available evidence on rates and timing of early onset of migraine prevention and identifies patient-level outcomes related to early onset prevention. This evidence-based scoping review identified all available clinical trial evidence regarding the early onset of prevention of migraine, under the hypothesis ‘Patients with migraine (episodic or chronic) report additional benefits when receiving an approved migraine preventive treatment that demonstrates an early onset of prevention’. Early onset of prevention was defined as migraine preventive benefits within 30 days post-administration. PubMed, EMBASE, and CINAHL were searched for publications between 1988 and 2020. Overall, 16 publications described 18 studies. All studies were conducted in approved treatments [four anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies and one chemodenervation agent] in patients with episodic/chronic migraine; no publications were identified for traditional oral agents for early migraine prevention. Compared to placebo, erenumab (three studies) reduced weekly migraine days within 1 week; fremanezumab (six studies) increased reports of no headache of at least moderate severity on Day 1 and significantly reduced migraine frequency within 1 week; galcanezumab (three studies) significantly reduced the mean number of patients with migraine beginning Day 1 and each day of the first week; eptinezumab (four studies) significantly reduced migraine attack likelihood on Day 1 by > 50% versus baseline; and onabotulinumtoxinA (two studies) reduced headache and migraine days within 1 week. Four publications described function, disability, and quality of life improvements as early as Week 4; none reported cost–benefit. Anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) and a chemodenervation agent (onabotulinumtoxinA) provide clinically relevant benefits during the first treatment week. Literature describing clinically relevant benefits regarding early onset of prevention in patients with migraine is limited.
KW - clinical benefits
KW - early onset
KW - migraine
KW - prevention
UR - http://www.scopus.com/inward/record.url?scp=85131310142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131310142&partnerID=8YFLogxK
U2 - 10.1177/17562864221095902
DO - 10.1177/17562864221095902
M3 - Review article
AN - SCOPUS:85131310142
SN - 1756-2856
VL - 15
JO - Therapeutic Advances in Neurological Disorders
JF - Therapeutic Advances in Neurological Disorders
ER -